Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Rent the Runway Inc (RENT) Price & Performance

ADMA Biologics Inc
Rent the Runway Inc

Price performance

Price movement over the last 24 hours

Key statistics

ADMA Biologics Inc vs Rent the Runway Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Rent the Runway Inc trades at $3.41 (market cap $115.40M). The key difference: ADMA Biologics Inc is far larger — about 18.5× Rent the Runway Inc's market cap. Which is the better fit depends on your goals.

ADMARENT
Market Cap
$2.13B$115.40M
Sector
HealthConsumer Cyclical
52-Week High
$20.38$9.39
52-Week Low
$7.60$3.10
Enterprise Value
$2.20B$275.50M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Rent the Runway Inc

RENT trades at $3.42, down 0.87% on the day, with a bearish technical signal. The company reported Q1 2026 revenue of $89.9 million, up 29.2% year-over-year, but continues to post net losses. Valuation ratios appear low with a P/E of 0.43 and P/S of 0.18, while negative equity of -$182.5 million and high debt levels pose financial risks. Recent leadership changes include the appointment of an interim CEO.

The outlook is mixed: strong revenue growth and low valuations suggest potential upside, but persistent losses, negative equity, and high leverage present significant risks. Analyst consensus is divided with 42% buy ratings, though no sell ratings exist. The stock's direction hinges on achieving profitability and managing debt.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Rent the Runway Inc

Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.

Read more on RENT